[Chinese expert consensus on diagnosis of early lung cancer (2023 Edition)].

Lung cancer is the leading cause of the incidence and mortality of malignant tumors in our country, seriously endangering people's lives and health. The treatment of lung cancer has made great progress in the past 10 years, and the 5-year survival rate of lung cancer in China has also increased from 16.1% to 19.7%, but about 75% of patients are still in advanced stages of lung cancer at the time of diagnosis, missing the best time for radical surgery. Early diagnosis can significantly improve the prognosis and survival of lung cancer patients. From the 5-year survival rate of lung cancer patients, it can be seen that the 5-year survival rate of stage Ⅰ patients was 77%-92%, while that of stage ⅢA-ⅣA patients was only 10%-36%, and there was a significant difference in the 5-year survival rate. Studies have shown that early-diagnosed and completely resected lung adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have 5-year disease-specific survival rates of 100% and 100%, respectively. Early diagnosis is the key to improving the prognosis of lung cancer. In order to further improve the level of early lung cancer diagnosis in China, especially the standardization in the diagnosis and evaluation of pulmonary nodules and early lung cancer, experts from the Lung Cancer Group of Chinese Thoracic Society formulated the "Chinese Expert Consensus on Diagnosis of Early Lung Cancer (2023 Edition)", on the basis of the actual situation in the field of diagnosis and treatment, with reference to the latest research data and relevant guidelines at home and abroad. Consensus on the application of artificial intelligence, big data and robotics, the Internet of Things and multidisciplinary cooperation in the diagnosis of early lung cancer, the management of pulmonary nodules and follow-up strategies for suspected early lung cancer, etc., were respectively recommended to provide references for clinicians in the diagnosis of early lung cancer, in order to further promote the early diagnosis of lung cancer in China.肺癌在我国居恶性肿瘤发病与死亡之首，严重危害到人民生命健康。近年来肺癌治疗取得了较大的进展，我国肺癌的5年生存率也从16.1%提高到19.7%，但仍有约75%的患者在诊断时处于肺癌晚期，错过了最佳根治性手术治疗时机。早期诊断可显著提高肺癌患者预后生存，从肺癌患者术后5年生存率可以看出，Ⅰ期患者术后5年生存率在77%~92%，而ⅢA~ⅣA期患者仅为10%~36%，5年生存率存在显著差异。研究显示早期诊断并完全切除的肺原位腺癌（AIS）及微浸润腺癌（MIA）术后5年疾病特异性生存率分别为100%和100%。早期诊断是提高肺癌预后的关键，为进一步提高我国早期肺癌诊断水平，尤其是肺结节暨早期肺癌诊断、评估中的准确性、规范性，中华医学会呼吸病学分会肺癌学组的专家针对国内肺癌早诊领域实际情况，参考国内外最新研究数据和相关指南，制定了《早期肺癌诊断中国专家共识（2023年版）》，共识围绕早期肺癌筛查人群、无创检查、有创检查、人工智能与大数据及机器人技术、物联网及多学科合作等在早期肺癌诊断中的应用、疑诊早期肺癌的肺结节管理及随访策略等7个方面分别给出推荐意见，为临床医生在早期肺癌诊断方面提供参考，以进一步推动我国早期肺癌诊断工作。.